Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Definition of response is critical when seeking to establish valid predictors of treatment success. However, response at the end of study or endpoint only provides one view of the overall clinical picture that is relevant in testing for predictors. The current study employed a classification technique designed to group subjects based on their rate of change over time, while simultaneously addressing the issue of controlling for baseline severity. METHODS: A set of latent class trajectory analyses, incorporating baseline level of symptoms, were performed on a sample of 344 depressed patients from a clinical trial evaluating the efficacy of cognitive behavior therapy and two antidepressant medications (escitalopram and duloxetine) in patients with major depressive disorder. RESULTS: Although very few demographic and illness-related features were associated with response rate profiles, the aggregated effect of candidate genetic variants previously identified in large pharmacogenetic studies and meta-analyses showed a significant association with early remission as well as nonresponse. These same genetic scores showed a less compelling relationship with endpoint response categories. In addition, consistent nonresponse throughout the study treatment period was shown to occur in different subjects than endpoint nonresponse, which was verified by follow-up augmentation treatment outcomes. CONCLUSIONS: When defining groups based on the rate of change, controlling for baseline depression severity may help to identify the clinically relevant distinctions of early response on one end and consistent nonresponse on the other.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“In particular, remission (Frank et al., 1991) has been identified as the goal of treatment for MDD due to its strong association with restoration of functioning and durability of wellness (Keller, 2004).”
BackgroundKeller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 2×
“The slower response to CBT versus antidepressant medications has been previously reported (Keller et al., 2000); nevertheless, the overall efficacy of the treatments does not differ by the end of 12weeks of treatment.”
BackgroundSelf-citationKapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
Fava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Sudden gains and critical sessions in cognitive-behavioral therapy for depression.
Tang, T. Z., & DeRubeis, R. J. (1999) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.67.6.894 · Cited by 684
Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder
McGrath, C. L., Kelley, M. E., Holtzheimer, P. E., Dunlop, B. W., Craighead, W. E., Franco, A. R., Craddock, R. C., & Mayberg, H. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.143 · Cited by 561 · cited 1×
“2018;35:992–1000.wileyonlinelibrary.com/journal/da Dunlop, Kelley, McGrath, Craighead, &Mayberg, 2015;McGrath et al., 2013; 2014).”
Self-citationSerretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529
The role of nonspecific factors in cognitive-behavior therapy for depression.
Ilardi, S. S., & Craighead, W. E. (1994) · Clinical Psychology: Science and Practice · doi:10.1111/j.1468-2850.1994.tb00016.x · Cited by 501
Self-citationReview and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
How Placebos Change the Patient's Brain
Benedetti, F., Carlino, E., & Pollo, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.81 · Cited by 446
Dunlop, B. W., Rajendra, J. K., Craighead, W. E., Kelley, M. E., McGrath, C. L., Choi, K. S., Kinkead, B., Nemeroff, C. B., & Mayberg, H. S. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050518 · Cited by 342
Self-citationSzegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341 · cited 11×
“Patients were randomized 1:1:1 to one of three possible phase 1 treatments over 12 weeks: (1) escitalopram (ESC): 10–20 mg/d, (2) duloxetine (DUL): 30–60 mg/d, or (3) CBT, 16 individual 1-hr sessions.”
BackgroundInfluentialPorcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331 · cited 3×
“In fact, a post hoc adjustment for the level of baseline depression is often employed when evaluating potential predictors of treatment outcome (Hunter et al., 2010; Porcelli et al., 2012).”
Lekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284 · cited 2×
“, 2007); (3) rs4713916 (FKBP5) (Lekman et al., 2008; Zou et al., 2010a); (4) rs1954787GRIK4 (Paddock et al.”
Gibbons, R. D., Hur, K., Brown, C. H., Davis, J. M., & Mann, J. J. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2044 · Cited by 271
Weitz, E. S., Hollon, S. D., Twisk, J., van Straten, A., Huibers, M. J. H., David, D., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W., Cristea, I. A., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1516 · Cited by 187
Self-citationLutz, W., Stulz, N., & Köck, K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.019 · Cited by 186 · cited 5×
“Combined profiles are preferred (Lutz et al., 2009; Muthen et al., 2011; Stulz et al., 2010; Uher et al., 2010), as they allow for comparison of response rates in different treatment groups as well as testing for treatment-specific predictors (i.”
BackgroundInfluentialPretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression
McGrath, C. L., Kelley, M. E., Dunlop, B. W., Holtzheimer III, P. E., Craighead, W. E., & Mayberg, H. S. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.005 · Cited by 139 · cited 1×
“Recent approaches for imaging biomarkers have demonstrated the utility of contrasting remitters and nonresponders at endpoint (Dunlop et al., 2015; McGrath et al., 2014).”
BackgroundSelf-citationDunlop, B. W., Binder, E. B., Cubells, J. F., Goodman, M. M., Kelley, M. E., Kinkead, B., Kutner, M., Nemeroff, C. B., Newport, D. J., Owens, M. J., et al. (2012) · Trials · doi:10.1186/1745-6215-13-106 · Cited by 136
Self-citationZou, Y.-F., Ye, D.-Q., Feng, X.-L., Su, H., Pan, F.-M., & Liao, F.-F. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.12.005 · Cited by 104
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Antidepressant response trajectories and associated clinical prognostic factors among older adults
Smagula, S. F., Butters, M. A., Anderson, S. J., Lenze, E. J., Dew, M. A., Mulsant, B. H., Lotrich, F. E., Aizenstein, H., & Reynolds, C. F. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1324 · Cited by 71 · cited 6×
“Baseline severity, therefore, remains the most significant predictor (Hunter et al., 2010; Lutz et al., 2009; Smagula et al., 2015; Stulz et al., 2010; Thibodeau et al., 2015; Wardenaar, Monden, Conradi, & de Jonge, 2015) as well as the most prominent characteristic of the classes.”
BackgroundMethodInfluentialZou, Y.-F., Wang, F., Feng, X.-L., Li, W.-F., Tao, J.-H., Pan, F.-M., Huang, F., & Su, H. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.08.019 · Cited by 61
Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression
Shelton, R. C., Andorn, A. C., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Watkin, J. G., & Detke, M. J. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32821c6189 · Cited by 39 · cited 1×
“, 2010) and may also reflect placebo responsiveness, which is highly relevant for clinical trials (Kasper, Spadone, Verpillat, & Angst, 2006; Shelton et al., 2007).”
Background
Cited by
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“In terms of ‘minimum duration’, some studies have shown that, while two weeks can be enough to observe an initial response, a stable response/remission is usually detectable after four weeks [37, 38].”
BackgroundSelf-citationDai, F., Wengler, K., He, X., Wang, J., Yang, J., Parsey, R. V., & DeLorenzo, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03292-9 · Cited by 12
Latent classes of symptom trajectories among major depressive disorder patients in China
Wang, Y., Li, J., Bian, W., Duan, Y., Geng, W., Jiang, J., Zhao, X., Li, T., Jiang, Y., Shi, L., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.144 · Cited by 5
Metadata
- Authors
- Kelley, M. E., Dunlop, B. W., Nemeroff, C. B., Lori, A., Carrillo-Roa, T., Binder, E. B., Kutner, M. H., Rivera, V. A., Craighead, W. E., & Mayberg, H. S.
- Venue
- Depression and Anxiety
- Publisher
- Wiley
- Published
- 2018-09-07
- Volume
- 35
- Issue
- 10
- Pages
- 992-1000
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W2892026058
- Cited by
- 43
- References
- 24
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.